1Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum[J]. Oncologist, 2005,10(5) : 345-356.
2Shepherd FA, Rodrigues J, Ciuleanu T, et al. Erlotinib in previously treated non-smell cell lung cancer[J]. N EngI J Med, 2005,353(2) : 123-132.
3Morse L,Calarese P. EGFR-targeted therapy and related skin toxicity[J]. Semin Oncol Nurs, 2006,22(3) : 152-162.
4Gatzemeier U,Pluzanska A,Szczesna A, et al. Phase Ⅲ study of erlotinib in combination with cisplatin and gemcitabine in advacced non-smell-cell lung cancer: the tarceva lung cancer investigation trial[J]. J Clin Oncol, 2007,25(12) : 1545-1552.
